GSK Reports Positive Phase III Results for Linerixibat in Treating Itch Associated with PBC GSK plc (LSE/NYSE: GSK) today announced positive results from its GLISTEN phase III trial evaluating linerixibat,…
Merck Animal Health and State of Kansas Announce $895 Million Investment in De Soto Manufacturing and R&D Facilities Merck Animal Health launches its largest economic development project to date Rahway,…
Johnson & Johnson Expands Global Commitment to Strengthen Nursing Workforce and Improve Healthcare Access Johnson & Johnson today announced the expansion of its efforts to champion the nursing workforce and…
Eli Lilly Announces Executive Leadership Changes to Propel Future Growth Eli Lilly and Company (NYSE: LLY) today announced a series of executive leadership transitions designed to strengthen its ability to…
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) stands as a unique global biopharmaceutical leader, delivering a wide range of medicines to patients around the world. With a legacy spanning…
Otsuka Pharmaceutical Signs Research Agreement with Keio University to Advance Psychedelic Treatment Infrastructure in Japan Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that it has signed a non-clinical (basic research)…
argenx SE (Euronext & Nasdaq: ARGX), a global immunology company focused on improving the lives of people with severe autoimmune diseases, today announced its financial results for the first quarter…
Strong FY2024 Performance and Strategic Outlook for FY2025 The company reported core revenue growth of 7.4% at actual exchange rates (AER) and 2.8% at constant exchange rates (CER) for fiscal…
90% of Adults with Chronic Hepatitis Delta Who Cleared Virus on Bulevirtide Stayed Clear Nearly 2 Years After Stopping Treatment Gilead Sciences, Inc. (Nasdaq: GILD) today announced final results from…
Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from multiple analyses which reinforce that Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union, is effective and generally well-tolerated for the treatment…
Enhertu Plus THP Shows Improved Safety and Efficacy Over Standard of Care in Early HER2-Positive Breast CancerAstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan), followed by a regimen of paclitaxel, trastuzumab,…
Novo Nordisk Reports Strong Operating Profit and Sales Growth, Updates 2025 Outlook Novo Nordisk announced a 22% increase in operating profit in Danish kroner, or 20% growth at constant exchange…